XNK Therapeutics logo
Svenska
Svenska
  • About XNK Therapeutics
    About XNK Therapeutics
    Close
    • Organisation
      Management
      Board of directors
      Advisors
      Collaborations and partners
    • Career
      Vacant positions
  • Our Science
    Our Science
    Close
    • Introduction to Cell Therapy
      The XNK Technology Platform
      Benefits
      Potential Indications
      Protection of intellectual property
    • Pipeline
      Clinical Trials
      ACP-001
      ISA-HC-NK
    • Research & Development
  • Investors
    Investors
    Close
    • General meetings
  • Media
    Media
    Close
    • Press releases
    • Subscribe
    • Presentations
  • Contact
  • About XNK Therapeutics
    • Organization
      • Management
      • Board of directors
      • Advisors
    • Collaborations and partners
    • Career
      • Vacant positions
  • Our Science
    • Introduction to Cell Therapy
    • The XNK Technology Platform
      • Benefits
      • Potential Indications
      • Protection of intellectual property
    • Pipeline
    • Clinical Trials
      • ACP-001
      • ISA-HC-NK
    • Research & Development
  • Investors
    • General meetings
  • Media
    • Press releases
    • Subscribe
    • Presentations
  • Contact

Press releases

2017
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • All years
December 15, 2017

XNK Therapeutics receives orphan drug designation from EMA

For more info: https://news.cision.com/se/xnk-therapeutics-ab/r/svenska-cellterapikandidaten-cellprotect-har-erhallit-sarlakemedelsstatus-for-behandling-av-multipel,c2415694

January 31, 2017

XNK Therapeutics granted US patent for method to treat MM with NK cells

XNK Therapeutics AB (“XNK”) announced today it received a patent from the US for its method of treating multiple myeloma with expanded NK cells. “Being granted this patent in the US is an…

  • Media
    • Press releases
    • Subscribe
    • Presentations

Subscribe

Read more about our protection of your personal data.

XNK Therapeutics AB

Hälsovägen 7, Novum
141 57 Huddinge
SWEDEN

Email: info@xnktherapeutics.com

© 2022 XNK Therapeutics

  • Cookies
  • Privacy Policy
  • Integritetspolicy avseende aktieägare